Is there a Role for Carbon Therapy in the Treatment of Gynecological Carcinomas? A Systematic Review

Wang, Lina; Wang, Xiaohu; Zhang, Qiuning; Ran, Juntao; Geng, Yichao; Feng, Shuangwu; Li, Chengcheng; Zhao, Xueshan

doi:10.2217/fon-2019-0187

Cited by 17 publications

(16 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a systematic review of eight clinical studies from NIRS, Wang et al concluded that carbon ion radiotherapy is safe and effective in the treatment for gynecologic cancers. The authors found lower rates of local recurrence at doses higher than 70 GyE for cervical cancer (95).…”

Section: Gynecologic Cancer Cervical Cancermentioning

confidence: 89%

Carbon Ion Therapy: A Modern Review of an Emerging Technology

et al. 2020

View full text Add to dashboard Cite

Radiation therapy is one of the most widely used therapies for malignancies. The therapeutic use of heavy ions, such as carbon, has gained significant interest due to advantageous physical and radiobiologic properties compared to photon based therapy. By taking advantage of these unique properties, carbon ion radiotherapy may allow dose escalation to tumors while reducing radiation dose to adjacent normal tissues. There are currently 13 centers treating with carbon ion radiotherapy, with many of these centers publishing promising safety and efficacy data from the first cohorts of patients treated. To date, carbon ion radiotherapy has been studied for almost every type of malignancy, including intracranial malignancies, head and neck malignancies, primary and metastatic lung cancers, tumors of the gastrointestinal tract, prostate and genitourinary cancers, sarcomas, cutaneous malignancies, breast cancer, gynecologic malignancies, and pediatric cancers. Additionally, carbon ion radiotherapy has been studied extensively in the setting of recurrent disease. We aim to provide a comprehensive review of the studies of each of these disease sites, with a focus on the current trials using carbon ion radiotherapy.

show abstract

Section: Gynecologic Cancer Cervical Cancermentioning

confidence: 89%

Carbon Ion Therapy: A Modern Review of an Emerging Technology

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Another current barrier to adoption in the United States is the lack of current randomized data to suggest a benefit of CIRT, although the development of a CIRT center in the United States has the potential to further develop new protocols and to advance preclinical research. Currently, early clinical prospective and retrospective studies have suggested both the safety and the efficacy of CIRT for a variety of disease sites, although there remains few phase III protocols [48][49][50][51][52][53][54][55][56][57][58][59][60]. Based on those early studies, multiple protocols are currently enrolling patients internationally [61].…”

Section: Discussionmentioning

confidence: 99%

Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States

Malouff

Vallow

Seneviratne

et al. 2020

International Journal of Particle Therapy

View full text Add to dashboard Cite

Purpose Carbon ion radiotherapy (CIRT) is an emerging radiotherapy modality with potential advantages over conventional photon-based therapy, including exhibiting a Bragg peak and greater relative biological effectiveness, leading to a higher degree of cell kill. Currently, 13 centers are treating with CIRT, although there are no centers in the United States. We aimed to estimate the number of patients eligible for a CIRT center in the United States. Materials and Methods Using the National Cancer Database, we analyzed the incidence of cancers frequently treated with CIRT internationally (glioblastoma, hepatocellular carcinoma, cholangiocarcinoma, locally advanced pancreatic cancer, non–small cell lung cancer, localized prostate cancer, soft tissue sarcomas, and specific head and neck cancers) diagnosed in the United States in 2015. The percentage and number of patients likely benefiting from CIRT was estimated with inclusion criteria from clinical trials and retrospective studies, and that ratio was applied to 2019 cancer statistics. An adaption correction rate was applied to estimate the potential number of patients treated with CIRT. Given the high dependency on prostate and lung cancers and the uncertain adoption of CIRT in those diseases, the data were then reanalyzed excluding those diagnoses. Results Of the 1 127 455 new cases of cancer diagnosed in the United States in 2015, there were 213 073 patients (18.9%) eligible for treatment with CIRT based on inclusion criteria. When applying this rate and the adaption correction rate to the 2019 incidence data, an estimated 89 946 patients (42.2% of those fitting inclusion criteria) are eligible for CIRT. Excluding prostate and lung cancers, there were an estimated 8922 patients (10% of those eligible for CIRT) eligible for CIRT. The number of patients eligible for CIRT is estimated to increase by 25% to 27.7% by 2025. Conclusion Our analysis suggests a need for CIRT in the United States in 2019, with the number of patients possibly eligible to receive CIRT expected to increase during the coming 5 to 10 years.

show abstract

“…Moreover, OS rates may vary between different MM sites. 5‐y OS rates were 37%‐50% in vulvar, 13%‐32% in vaginal, and 10% in cervical MM cases 41 . Surgery, photon beam RT, chemotherapy, and PD‐1 checkpoint inhibitors were shown to not significantly improve OS rates 42,43 ; however, CIRT shows promising results for treating gynecological MMs.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Zhang

et al. 2020

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Malignant melanomas (MMs) originate from melanocytes in the basal layer of the epidermis, and they are characterized by high malignancy, early metastasis, poor prognosis, and high mortality. Depending on their location, MMs can be classified as cutaneous, uveal or mucosal. Previous studies suggest that average morbidity rates are 16.2 per 100 000 in the United States and 0.383 per 100 000 in Japan. 1 However, MMs incidence increased continuously worldwide. 2,3 MMs were the fifth most common cancer in men and the sixth most common cancer in women in 2018. According to the American Association of Cancer (AJCC) TNM staging system, the 5-year overall survival (5-y OS) rates are approximately 98.2% in patients at stages I/II, 61.7% at stage III, and 15.2% at stage IV. 4 Although stage I MMs are typically associated with good prognoses after surgical treatment only, achieving negative margins in all patients was difficult. Currently available treatment options for patients with MM include radiotherapy (RT), chemotherapy, targeted therapy, and immunotherapy. Adjuvant therapies were

show abstract

Is there a Role for Carbon Therapy in the Treatment of Gynecological Carcinomas? A Systematic Review

Cited by 17 publications

References 63 publications

Carbon Ion Therapy: A Modern Review of an Emerging Technology

Carbon Ion Therapy: A Modern Review of an Emerging Technology

Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States

Efficacy and safety of carbon‐ion radiotherapy for the malignant melanoma: A systematic review

Contact Info

Product

Resources

About